CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
Status:
Active, not recruiting
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric
Antigen Receptor (CAR) redirected autologous T-cells in children with high risk, relapsed
CD19+ haematological malignancies.